Regulatory Challenges in the CIS and Russia - TOPRA In CEE WebinarNovember 22, 2023
European and US regulators agree on mutual recognition of inspections of medicines manufacturers
Transatlantic agreement will help to make better use of inspection capacity and reduce duplication
Regulators in the European Union (EU) and the United States (US) have agreed to recognise inspections of manufacturing sites for human medicines conducted in their respective territories on both sides of the Atlantic.
Each year, national competent authorities from the EU and the US Food and Drug AdministrationExternal link icon (FDA) inspect many production sites of medicinal products in the EU, the US and elsewhere in the world, to ensure that these sites operate in compliance with good manufacturing practice (GMP). Under the new agreement, EU and US regulators will rely on each other’s inspections in their own territories. In future, the need for an EU authority to inspect a site located in the US, or vice versa, will be limited to exceptional circumstances.
The agreement will enable both the EU authorities and the FDA to make better use of their inspection resources to help them to focus on other parts of the world where active pharmaceutical ingredients (APIs) and medicines for the EU or US markets are manufactured. This will ensure that patients can rely on the quality, safety and efficacy of all medicines, no matter where they have been produced. Around 40% of finished medicines marketed in the EU come from overseas and 80% of the manufacturers of APIs for medicines available in the EU are located outside the Union.
Read full article HERE
Особенности выбора типа Пользовательского тестирования листка-вкладыша в ЕАЭСNovember 01, 2023
Features of Choosing the Type of PIL RUT in EAEUNovember 01, 2023
PIL Readability User Testing in EAEU Special Autumn OfferOctober 25, 2023
Специальное Осеннее Предложение по пользовательскому тестированию листка-вкладышаOctober 24, 2023
PIL Readability Testing is Mandatory in EAEUFebruary 15, 2022
Пользовательское тестирование по ЕАЭС – обязательная процедураFebruary 14, 2022
One More Inpharmatis Team Member Gets PhD in Pharmaceutical SciencesJanuary 27, 2022
В штате Inpharmatis стало на одного доктора фармацевтических наук большеJanuary 27, 2022
Pharma 4.0: Data-Driven RegulationJanuary 18, 2022